Our pipeline
We have an expertise in developing medicines for patients treated by specialist physicians, and for discovering new therapies for rare, life-threatening genetic disease.
| Indication | Project | Phase | Estimated submission | Estimated launch |
| SPECIALTY PHARMA | ||||
| ADHD | INTUNIV (Canada) | Registration | ||
| ADHD | VYVANSE (EU) | 3 | 2011 | 2012 |
| ADHD | INTUNIV (EU) | 3 | ||
| Diverticulitis | LIALDA/MEZAVANT | 3 | 2012 | 2013 |
| Chronic Kidney disease | FOSRENOL (US) | Pre-registration | ||
| Essential Thrombocythaemia | XAGRID (Japan) | 3 | ||
| Chronic constipation in men | RESOLOR (EU) | 3 | ||
| Major Depressive Disorder (MDD) | VYVANSE | 3 | ||
| Other non-ADHD users | VYVANSE | 2 | ||
| Negative symptoms and cognitive impairment in schizophrenia | VYVANSE | 2 | ||
| Excessive Daytime Sleepiness (EDS) | VYVANSE | 2 | ||
| Binge Eating Disorder (BED) | VYVANSE | 2 | ||
| PPI-refractory Gastroesophageal Reflux Disease (GERD) | SPD 557 (M0003) | 2 | ||
| Ascites | SPD 556 (M0002) | 2 | ||
| Arteriovenous grafts in hemodialysis patients | SPD 535 | 2 | 2013–2016 | |
| ADHD | Guanfacine Carrier Wave | 1 | ||
| Pain | Carrier Wave& | 1 | ||
| HUMAN GENETIC THERAPIES | ||||
| Fabry Disease | REPLAGAL (US) | Registration | ||
| Duchenne Muscular Dystrophy (DMD)(1) | HGT 4510 | 2 | ||
| Hunter syndrome CNS | HGT 2310 | 1-2 | 2013–2016 | |
| Metachromatic Leukodystrophy ('MLD') | HGT 1110 | Pre-clinical | 2013–2016 | |
| Sanfilippo A syndrome | HGT 1410 | 1-2 | 2013–2016 | |
| Santaris collaboration | 3 targets | Pre-clinical | 2013–2016 | |
| REGENERATIVE MEDICINE | ||||
| Diabetic Foot Ulcers (DFU) | DERMAGRAFT (Canada) | Registration | ||
Notes:
(1) Currently on clinical hold
